{
    "nct_id": "NCT04262466",
    "official_title": "Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers",
    "inclusion_criteria": "1. ECOG PS 0 or 1\n2. HLA-A*02:01 positive\n3. PRAME positive tumor\n4. Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies\n5. If applicable, must agree to use highly effective contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Symptomatic or untreated central nervous system metastasis\n2. Recent bowel obstruction\n3. Ongoing ascites or effusion requiring recent drainages\n4. Significant immune-mediated adverse event with prior immunotherapy (patients in checkpoint inhibitor combination treatment)\n5. Inadequate washout from prior anticancer therapy\n6. Significant ongoing toxicity from prior anticancer treatment\n7. Out-of-range laboratory values\n8. Clinically significant lung, heart, or autoimmune disease\n9. Ongoing requirement for immunosuppressive treatment\n10. Prior solid organ or bone marrow transplant\n11. Active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection\n12. Significant secondary malignancy\n13. Hypersensitivity to study drug or excipients\n14. Antibiotics, vaccines or surgery within 2-4 weeks prior to the first dose of study intervention\n15. Pregnant or lactating\n16. Any other contraindication for applicable combination partner based on local prescribing information",
    "miscellaneous_criteria": ""
}